Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.
Authors
Shohei Udagawa
Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Shohei Udagawa , Hiroki Osumi , Akira Ooki , Takeru Wakatsuki , Shota Fukuoka , Koichiro Yoshino , Mikako Tamba , Mariko Ogura , Daisuke Takahari , Keisho Chin , Kensei Yamaguchi , Eiji Shinozaki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 142)
DOI
10.1200/JCO.2024.42.3_suppl.142
Abstract #
142
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).
First Author: Jenny F. Seligmann
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC).
First Author: Vanessa Wong
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz